Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

被引：0
|
作者：
Andrea Camerini
Cheti Puccetti
Sara Donati
Chiara Valsuani
Maria Cristina Petrella
Gianna Tartarelli
Paolo Puccinelli
Domenico Amoroso
机构：
[1] Versilia Hospital and Istituto Toscano Tumori,Medical Oncology
来源：
BMC Cancer | / 15卷
关键词：
Elderly; Non-small-cell lung cancer; Metronomic vinorelbine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
    David Rossi
    Donatella Dennetta
    Marcello Ugolini
    Vincenzo Catalano
    Paolo Alessandroni
    Paolo Giordani
    Anna Maria Baldelli
    Virginia Casadei
    Francesco Graziano
    S. Luzi Fedeli
    Targeted Oncology, 2010, 5 : 231 - 235
  • [42] Vinorelbine - A review of its use in elderly patients with advanced non-small cell lung cancer
    Curran, MP
    Plosker, GL
    DRUGS & AGING, 2002, 19 (09) : 695 - 721
  • [43] Metronomic Oral Vinorelbine as First Line Treatment in Elderly (>65 Year) Patients with Advanced NSCLC
    Lumachi, Franco
    Del Conte, Alessandro
    Saracchini, Silvana
    Mazza, Francesco
    Ubiali, Paolo
    Basso, Stefano
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S907 - S907
  • [44] Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer
    Inoue, A
    Kunitoh, H
    Mori, K
    Nukiwa, T
    Fukuoka, M
    Saijo, N
    LUNG CANCER, 2002, 38 (02) : 205 - 209
  • [45] Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Price, Katharine A.
    Azzoli, Christopher G.
    Krug, Lee M.
    Pietanza, Maria C.
    Rizvi, Naiyer A.
    Pao, William
    Kris, Mark G.
    Riely, Gregory J.
    Heelan, Robert T.
    Arcila, Maria E.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1623 - 1629
  • [46] Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients
    Grigorescu, A. C.
    Bala, C.
    JOURNAL OF BUON, 2013, 18 (01): : 188 - 194
  • [47] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
    D. Binder
    H. Schweisfurth
    C. Grah
    C. Schäper
    B. Temmesfeld-Wollbrück
    G. Siebert
    N. Suttorp
    T. Beinert
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 143 - 150
  • [48] Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: results of a multicentre randomized phase II trial
    Binder, D.
    Schweisfurth, H.
    Grah, C.
    Schaeper, C.
    Temmesfeld-Wollbrueck, B.
    Siebert, G.
    Suttorp, N.
    Beinert, T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 143 - 150
  • [49] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Hyeong Su Kim
    Jung Han Kim
    Byounghoon Kim
    Hyun Chang Choi
    Jung Hye Kwon
    Dae Ro Choi
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1591 - 1597
  • [50] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Kim, Hyeong Su
    Kim, Jung Han
    Kim, Byounghoon
    Choi, Hyun Chang
    Kwon, Jung Hye
    Choi, Dae Ro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1591 - 1597
12345